MicroRNA‑34a expression affects breast cancer invasion in vitro and patient survival via downregulation of E2F1 and E2F3 expression Retraction in /10.3892/or.2024.8841

Han,Rui; Zhao,Jing; Lu,Lingeng

doi:10.3892/or.2020.7549

MicroRNA‑34a expression affects breast cancer invasion in vitro and patient survival via downregulation of E2F1 and E2F3 expression

Retraction in: /10.3892/or.2024.8841

Authors:
- Rui Han
- Jing Zhao
- Lingeng Lu
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, P.R. China, Department of Chronic Disease Epidemiology, Yale School of Public Health, School of Medicine, Yale University, New Haven, CT 06520, USA
Published online on: March 18, 2020 https://doi.org/10.3892/or.2020.7549
Pages: 2062-2072

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is the most common cancer type and the leading cause of cancer‑associated mortality in women across the majority of countries. In general, the incidence of breast cancer has been decreasing in developed countries over the previous 20 years, while it has increased in the other areas, such as the Asian‑Pacific region. MicroRNA‑34a (miR‑34a) targets stem cell‑associated transcription factors E2F1/E2F3, and may have clinical relevance in breast cancer. The present study aimed to investigate the association between miR‑34a/E2F1/E2F3 and patient survival in breast cancer, as well as the underlying molecular mechanism of miR‑34a in suppressing factors associated with tumor aggressiveness in vitro. Kaplan‑Meier survival curves were constructed and a meta‑analysis was performed to analyze the association of miR‑34a, E2F1 and E2F3 expression and overall survival in breast cancer, and the differential expression levels of E2F1 and E2F3 between breast cancer and normal breast tissues was assessed using publicly accessed datasets. Then 2D and 3D experiments on cell cultures were performed in vitro on both T‑47D and MDA‑MB‑231 cells to investigate the cancer biology of miR‑34a and its effect on E2F1 and E2F3 expression using reverse transcription‑quantitative PCR. Then, caspase‑3 (CASP3) activity was measured using a CaspACE™ assay system. E2F1 and E2F3 expression levels were upregulated in breast cancer, compared with normal breast tissues. Both high miR‑34a, and low E2F1 and E2F3 mRNA levels were positively associated with longer survival times in patients with breast cancer. The in vitro 2D and 3D cell experiments revealed that overexpression of miR‑34a significantly downregulated the expression of E2F1 and E2F3, and increased CASP3 activity in both T‑47D and MDA‑MB‑231 cells, and that miR‑34a treatment inhibited tumor cell proliferation, migration and invasiveness, as well as 3D spheroid formation. Thus, miR‑34a influences the aggressiveness of breast cancer and patient survival, and is a potential therapeutic tool in the clinical management of breast cancer.

View Figures

View References

1	Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C and Negri E: European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol. 30:781–787. 2019. View Article : Google Scholar
2	Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Nabieva N, Taran FA, Ettl J, Lüftner D, Belleville E, et al: Update breast cancer 2019 Part 1-implementation of study results of novel study designs in clinical practice in patients with early breast cancer. Geburtshilfe Frauenheilkd. 79:256–267. 2019. View Article : Google Scholar :
3	Janni W, Schneeweiss A, Müller V, Wöckel A, Lux MP, Hartkopf AD, Nabieva N, Taran FA, Tesch H, Overkamp F, et al: Update breast cancer 2019 Part 2-implementation of novel diagnostics and therapeutics in advanced breast cancer patients in clinical practice. Geburtshilfe Frauenheilkd. 79:268–280. 2019. View Article : Google Scholar :
4	Li N, Long B, Han W, Yuan S and Wang K: microRNAs: Important regulators of stem cells. Stem Cell Res Ther. 8:1102017. View Article : Google Scholar :
5	Zhao K, Cheng J, Chen B, Liu Q, Xu D and Zhang Y: Circulating microRNA-34 family low expression correlates with poor prognosis in patients with non-small cell lung cancer. J Thorac Dis. 9:3735–3746. 2017. View Article : Google Scholar :
6	Tao ZQ, Shi AM, Li R, Wang YQ, Wang X and Zhao J: Role of microRNA in prostate cancer stem/progenitor cells regulation. Eur Rev Med Pharmacol Sci. 20:3040–3044. 2016.
7	Gangopadhyay S, Nandy A, Hor P and Mukhopadhyay A: Breast cancer stem cells: A novel therapeutic target. Clin Breast Cancer. 13:7–15. 2013. View Article : Google Scholar
8	Alizadeh S, Ghader Azizi S, Soleimani M, Farshi Y and Kashani Khatib Z: The role of MicroRNAs in myeloproliferative neoplasia. Int J Hematol Oncol Stem Cell Res. 10:172–185. 2016.
9	Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D, Purow B and Abounader R: microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle. 9:1031–1036. 2010. View Article : Google Scholar :
10	Li J, Lam M, Iorns E, Gunn W, Tan FE, Lomax J, Errington TM and Massagué J: Registered report: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Elife. 4:e064342015. View Article : Google Scholar :
11	Craig V, Tzankov A, Flori M, Schmid CA, Bader AG and Müller A: Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Leukemia. 26:2421–2424. 2012. View Article : Google Scholar
12	Tammali R, Saxena A, Srivastava SK and Ramana KV: Aldose reductase regulates vascular smooth muscle cell proliferation by modulating G1/S phase transition of cell cycle. Endocrinology. 151:2140–2150. 2010. View Article : Google Scholar :
13	Lee M, Oprea-Ilies G and Saavedra HI: Silencing of E2F3 suppresses tumor growth of Her2+ breast cancer cells by restricting mitosis. Oncotarget. 6:37316–37334. 2015. View Article : Google Scholar :
14	Hollern DP, Honeysett J, Cardiff RD and Andrechek ER: The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer. Mol Cell Biol. 34:3229–3243. 2014. View Article : Google Scholar :
15	Knoll S, Emmrich S and Pützer BM: The E2F1-miRNA cancer progression network. Adv Exp Med Biol. 774:135–147. 2013. View Article : Google Scholar
16	Julian LM and Blais A: Transcriptional control of stem cell fate by E2Fs and pocket proteins. Front Genet. 6:1612015. View Article : Google Scholar :
17	Bellmunt J: Stem-like signature predicting disease progression in early stage bladder cancer. The role of E2F3 and SOX4. Biomedicines. 6(pii): E852018. View Article : Google Scholar
18	Farra R, Dapas B, Grassi M, Benedetti F and Grassi G: E2F1 as a molecular drug target in ovarian cancer. Expert Opin Ther Targets. 23:161–164. 2019. View Article : Google Scholar
19	Fang Y, Gu X, Li Z, Xiang J and Chen Z: miR-449b inhibits the proliferation of SW1116 colon cancer stem cells through downregulation of CCND1 and E2F3 expression. Oncol Rep. 30:399–406. 2013. View Article : Google Scholar
20	Ren J, Ding L, Xu Q, Shi G, Li X, Li X, Ji J, Zhang D, Wang Y, Wang T and Hou Y: LF-MF inhibits iron metabolism and suppresses lung cancer through activation of P53-miR-34a-E2F1/E2F3 pathway. Sci Rep. 7:7492017. View Article : Google Scholar :
21	Han R, Chen X, Li Y, Zhang S, Li R and Lu L: MicroRNA-34a suppresses aggressiveness of hepatocellular carcinoma by modulating E2F1, E2F3, and Caspase-3. Cancer Manag Res. 11:2963–2976. 2019. View Article : Google Scholar :
22	Santos M, Martínez-Fernández M, Dueñas M, García-Escudero R, Alfaya B, Villacampa F, Saiz-Ladera C, Costa C, Oteo M, Duarte J, et al: In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer. Cancer Res. 74:6565–6577. 2014. View Article : Google Scholar :
23	Suzuki T, Yasui W, Yokozaki H, Naka K, Ishikawa T and Tahara E: Expression of the E2F family in human gastrointestinal carcinomas. Int J Cancer. 81:535–538. 1999. View Article : Google Scholar
24	Gao Y, Feng B, Lu L, Han S, Chu X, Chen L and Wang R: MiRNAs and E2F3: A complex network of reciprocal regulations in human cancers. Oncotarget. 8:60624–60639. 2017.
25	Liu X and Wu X: Utilizing matrigel transwell invasion assay to detect and enumerate circulating tumor cells. Methods Mol Biol. 634:277–282. 2017. View Article : Google Scholar
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
27	Brown MF, Leibowitz BJ, Chen D, He K, Zou F, Sobol RW, Beer-Stolz D, Zhang L and Yu J: Loss of caspase-3 sensitizes colon cancer cells to genotoxic stress via RIP1-dependent necrosis. Cell Death Dis. 6:e17292015. View Article : Google Scholar :
28	Holliday DL and Speirs V: Choosing the right cell line for breast cancer research. Breast Cancer Res. 13:2152011. View Article : Google Scholar :
29	Li Y, Sturgis EM, Zhu L, Cao X, Wei Q, Zhang H and Li G: E2F transcription factor 2 variants as predictive biomarkers for recurrence risk in patients with squamous cell carcinoma of the oropharynx. Mol Carcinog. 56:1335–1343. 2017. View Article : Google Scholar :
30	Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 486:346–352. 2012. View Article : Google Scholar :
31	Altundag K: Patients with invasive lobular and ductal carcinoma or pleomorphic lobular carcinoma might increase pathologic complete response rate and lower mastectomy rates compared to classical lobular type. J Surg Oncol. 20:5652019. View Article : Google Scholar
32	Liu YY, Yu TJ and Liu GY: The predictive value of the prognostic staging system in the 8th edition of the American Joint Committee on Cancer for triple-negative breast cancer: A SEER population-based analysis. Future Oncol. 15:391–400. 2019. View Article : Google Scholar
33	Adams BD, Parsons C and Slack FJ: The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas. Expert Opin Ther Targets. 20:737–753. 2016. View Article : Google Scholar
34	Ren FH, Yang H, He RQ, Lu JN, Lin XG, Liang HW, Dang YW, Feng ZB, Chen G and Luo DZ: Analysis of microarrays of miR-34a and its identification of prospective target gene signature in hepatocellular carcinoma. BMC Cancer. 18:122018. View Article : Google Scholar :
35	Sun TY, Xie HJ, Li Z, Kong LF, Gou XN, Li DJ, Shi YJ and Ding YZ: miR-34a regulates HDAC1 expression to affect the proliferation and apoptosis of hepatocellular carcinoma. Am J Transl Res. 9:103–114. 2017.
36	Fang Z, Gong C, Liu H, Zhang X, Mei L, Song M, Qiu L, Luo S, Zhu Z, Zhang R, et al: E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2. Biochem Biophys Res Commun. 464:407–415. 2015. View Article : Google Scholar
37	Pulikkan JA, Peramangalam PS, Dengler V, Ho PA, Preudhomme C, Meshinchi S, Christopeit M, Nibourel O, Müller-Tidow C, Bohlander SK, et al: C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood. 116:5638–5649. 2010. View Article : Google Scholar :
38	Cao Q, Xia Y, Azadniv M and Crispe IN: The E2F-1 transcription factor promotes caspase-8 and bid expression, and enhances Fas signaling in T cells. J Immunol. 173:1111–1117. 2004. View Article : Google Scholar
39	Li ZH, Weng X, Xiong QY, Tu JH, Xiao A, Qiu W, Gong Y, Hu EW, Huang S and Cao YL: miR-34a expression in human breast cancer is associated with drug resistance. Oncotarget. 8:106270–106282. 2017.
40	Rokavec M, Li H, Jiang L and Hermeking H: The p53/miR-34 axis in development and disease. J Mol Cell Biol. 6:214–230. 2014. View Article : Google Scholar
41	Bader AG: miR-34-a microRNA replacement therapy is headed to the clinic. Front Genet. 3:1202012. View Article : Google Scholar :
42	Bu P, Wang L, Chen KY, Srinivasan T, Murthy PK, Tung KL, Varanko AK, Chen HJ, Ai Y, King S, et al: A miR-34a-Numb Feedforward loop triggered by inflammation regulates asymmetric stem cell division in intestine and colon cancer. Cell Stem Cell. 18:189–202. 2016. View Article : Google Scholar :
43	Tazawa H, Tsuchiya N, Izumiya M and Nakagama H: Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA. 104:15472–15477. 2007. View Article : Google Scholar
44	Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z and Oren M: Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 26:731–743. 2007. View Article : Google Scholar
45	Zauli G, Voltan R, di Iasio MG, Bosco R, Melloni E, Sana ME and Secchiero P: miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res. 17:2712–2724. 2011. View Article : Google Scholar
46	Yamamura S, Saini S, Majid S, Hirata H, Ueno K, Chang I, Tanaka Y, Gupta A and Dahiya R: MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma. Carcinogenesis. 33:294–300. 2012. View Article : Google Scholar
47	Hao Q, Lu X, Liu N, Xue X, Li M, Zhang C, Qin X, Li W, Shu Z, Song B, et al: Posttranscriptional deregulation of Src due to aberrant miR34a and miR203 contributes to gastric cancer development. BMB Rep. 46:316–321. 2013. View Article : Google Scholar :
48	Wei WY, Yan LH, Wang XT, Li L, Cao WL, Zhang XS, Zhan ZX, Yu H, Xie YB and Xiao Q: E2F-1 overexpression inhibits human gastric cancer MGC-803 cell growth in vivo. World J Gastroenterol. 21:491–501. 2015. View Article : Google Scholar :
49	Atkinson EA, Barry M, Darmon AJ, Shostak I, Turner PC, Moyer RW and Bleackley RC: Cytotoxic T lymphocyte-assisted suicide. Caspase 3 activation is primarily the result of the direct action of granzyme B. J Biol Chem. 273:21261–21266. 1998. View Article : Google Scholar
50	Huang Q, Zheng Y, Ou Y, Xiong H, Yang H, Zhang Z, Chen S and Ye Y: miR-34a/Bcl-2 signaling pathway contributes to age-related hearing loss by modulating hair cell apoptosis. Neurosci Lett. 661:51–56. 2017. View Article : Google Scholar
51	Noble P, Vyas M, Al-Attar A, Durrant S, Scholefield J and Durrant L: High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival. Br J Cancer. 108:2097–2105. 2013. View Article : Google Scholar :
52	Jakubowska K, Guzińska-Ustymowicz K, Famulski W, Cepowicz D, Jagodzińska D and Pryczynicz A: Reduced expression of caspase-8 and cleaved caspase-3 in pancreatic ductal adenocarcinoma cells. Oncol Lett. 11:1879–1884. 2016. View Article : Google Scholar :
53	Sheldon LA: Inhibition of E2F1 activity and cell cycle progression by arsenic via retinoblastoma protein. Cell Cycle. 16:2058–2072. 2017. View Article : Google Scholar :
54	Kent LN, Bae S, Tsai SY, Tang X, Srivastava A, Koivisto C, Martin CK, Ridolfi E, Miller GC, Zorko SM, et al: Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma. J Clin Invest. 127:830–842. 2017. View Article : Google Scholar :
55	Zhou Y, Xiong M, Niu J, Sun Q, Su W, Zen K, Dai C and Yang J: Secreted fibroblast-derived miR-34a induces tubular cell apoptosis in fibrotic kidney. J Cell Sci. 127:4494–4506. 2014. View Article : Google Scholar
56	Ding N, Wu H, Tao T and Peng E: NEAT1 regulates cell proliferation and apoptosis of ovarian cancer by miR-34a-5p/BCL2. Onco Targets Ther. 10:4905–4915. 2017. View Article : Google Scholar :
57	Li LH, Tu QY, Deng XH, Xia J, Hou DR, Guo K and Zi XH: Mutant presenilin2 promotes apoptosis through the p53/miR-34a axis in neuronal cells. Brain Res. 1662:57–64. 2017. View Article : Google Scholar
58	Chen YC and Yoon E: High-throughput cancer cell sphere formation for 3D cell culture. Methods Mol Biol. 1612:281–291. 2017. View Article : Google Scholar